On October 25, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, reported its collaboration with Urology San Antonio, PA in Anixa’s ongoing Cchek prostate cancer study (Press release, Anixa Biosciences, OCT 25, 2019, View Source [SID1234542520]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Urology San Antonio, PA joins a large and growing team of collaborators advancing the Cchek liquid biopsy technology toward commercialization.
Study enrollment will be led by board-certified urologist Dr. David R. Talley.
"We are excited to join Anixa’s Cchek prostate cancer study, and through this collaboration we hope to improve patient care," stated Dr. Talley. "Prostate cancer is one of the most common types of cancer in men, and if detected early, has a better chance of successful treatment. While several advancements have been made in recent years, there is much room for improvement in detecting the disease early and efficiently."
Dr. Amit Kumar, Anixa’s Chief Executive Officer, stated, "We are pleased to have Urology San Antonio join our Cchek prostate cancer study. The continued addition of influential physicians and urology practices to our team of collaborators is key to the eventual commercialization of our Cchek Prostate Cancer Confirmation test. We are confident this technology utilizing flow cytometry coupled with artificial intelligence to detect cancer early will make a significant impact in the overall testing paradigm."
About Cchek
Cchek is an early cancer detection technology, which measures a patient’s immunological response to a malignancy by analyzing immune system cells in peripheral blood. The goal is to utilize the technology to determine a patient’s cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure. Further, conventional methods using current cancer screening tests often lack accuracy and reliability. Anixa’s orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method with greater affordability, efficacy and efficiency. To date, Anixa has successfully used Cchek to detect the presence of 20 different cancers including lung, colon, breast and prostate. The robust cancer detection performance of Cchek makes it a platform from which multiple cancer diagnostic tests may be developed. The first such test, a prostate cancer confirmation test, is slated for commercial launch by the end of 2019.